Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

Satoshi Ikegame, Mohammed N. A. Siddiquey, Chuan-Tien Hung, Griffin Haas, Luca Brambilla, Kasopefoluwa Y. Oguntuyo, Shreyas Kowdle, Hsin-Ping Chiu, Christian S. Stevens, Ariel Esteban Vilardo, Alexis Edelstein, Claudia Perandones, Jeremy P. Kamil and Benhur Lee ()
Additional contact information
Satoshi Ikegame: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Mohammed N. A. Siddiquey: Louisiana State University Health Shreveport
Chuan-Tien Hung: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Griffin Haas: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Luca Brambilla: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Kasopefoluwa Y. Oguntuyo: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Shreyas Kowdle: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Hsin-Ping Chiu: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Christian S. Stevens: Department of Microbiology at the Icahn School of Medicine at Mount Sinai
Ariel Esteban Vilardo: National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán
Alexis Edelstein: National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán
Claudia Perandones: National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán
Jeremy P. Kamil: Louisiana State University Health Shreveport
Benhur Lee: Department of Microbiology at the Icahn School of Medicine at Mount Sinai

Nature Communications, 2021, vol. 12, issue 1, 1-11

Abstract: Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 180 million people since its identification as the cause of the current COVID-19 pandemic. The rapid pace of vaccine development has resulted in multiple vaccines already in use worldwide. The contemporaneous emergence of SARS-CoV-2 ‘variants of concern’ (VOC) across diverse geographic locales underscores the need to monitor the efficacy of vaccines being administered globally. All WHO designated VOC carry spike (S) polymorphisms thought to enable escape from neutralizing antibodies. Here, we characterize the neutralizing activity of post-Sputnik V vaccination sera against the ensemble of S mutations present in alpha (B.1.1.7) and beta (B.1.351) VOC. Using de novo generated replication-competent vesicular stomatitis virus expressing various SARS-CoV-2-S in place of VSV-G (rcVSV-CoV2-S), coupled with a clonal 293T-ACE2 + TMPRSS2 + cell line optimized for highly efficient S-mediated infection, we determine that only 1 out of 12 post-vaccination serum samples shows effective neutralization (IC90) of rcVSV-CoV2-S: B.1.351 at full serum strength. The same set of sera efficiently neutralize S from B.1.1.7 and exhibit only moderately reduced activity against S carrying the E484K substitution alone. Taken together, our data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-24909-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24909-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-24909-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().